NCT00671216View on ClinicalTrials.gov

A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects.

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 20, 2008

Primary Completion Date

July 7, 2008

Study Completion Date

July 7, 2008

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

GSK233705

Subjects will receive 200 (mcg) microgram once daily as a single dose

DRUG

GW642444

Subjects will receive 50 mcg once daily as a single dose

DRUG

GSK233705 and GW642444

Subjects will receive combination of GSK233705 200 mcg and GW642444 50 mcg as a single oral dose

DRUG

Placebo

Placebo matching study medication will be inhaled by subjects

Trial Locations (1)

NW10 7NS

GSK Investigational Site, London

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY